广西师范大学二级教授、博士生导师、“药用资源化学与药物分子工程国家重点实验室”学术带头人、广西师范大学国际文化教育学院党委书记/港澳台事务办公室主任。博士毕业于中国科学院福建物质结构研究所。2006年至2010年在美国能源部-布鲁克海文国家实验室从事博士后研究，期间参与2项美国国立卫生院重大项目。目前，主持/完成7项国家自然科学基金、1项广西自然科学基金-创新团队项目、1项广西高校高水平创新团队项目、1项广西自然科学基金-重大项目、1项广西自然科学基金-杰出青年项目、2项广西自然科学基金-重点项目。在Nature Communications、Angewandte Chemie-International Edition、Journal of Medicinal Chemistry等国际权威期刊发表90余篇药学研究论文，受邀在《Coordination Chemistry Reviews》等TOP期刊撰写综述和专题评论，授权国家发明专利23项；担任《Current Pharmaceutical Design》客座编辑、《Pharmaceutical Fronts》、《Current Cancer Therapy Reviews》和《中国现代应用药学》编委；入选全球前2%顶尖科学家榜单，获得广西“八桂学者”、广西“十百千人才工程”第二层次人选、广西高等学校卓越学者、广西科学技术特别贡献奖、广西自然科学一等奖、广西青年科技奖。
代表性论文：
1. Man XY, Zhang ZL, Liang H*, Yang F*. Single-molecular theranostic metal complexes: Integrating bio-imaging and cancer therapy. Coordination Chemistry Reviews, 2026, 549, 217356. (化学顶级综述，IF=23.5)
2. Gou Y, Huang GJ, Li JL, Yang F*, Liang H*. Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents. Coordination Chemistry Reviews, 2021, 441, 213975.
3. Man XY, Li WJ, Zhu MH, Li SH, Xu G, Zhang ZL, H Liang*, Yang F*. Anticancer tetranuclear Cu(I) complex catalyzes a click reaction to synthesize a chemotherapeutic agent in situ to achieve targeted dual-agent combination therapy for cancer. Angewandte Chemie-International Edition, 2024, 63, e202411846.(化学顶级期刊，IF=16.9)
4. Yue JP, Zhang Y, Liang WG, Gou XW, Lee P, Liu H, Lyv WQ, Tang WJ, Yang F*, Liang H*, Wu XY*. In vivo epidermal migration requires focal adhesion targeting of ACF7. Nature Communications, 2016, 7, 11692. (综合性顶级期刊，IF=15.7)
5. Ma YL, Yue JP, Zhang Y, Shi CZ, Odenwald M, Liang WG, Wei Q, Goel A, Gou XW, Zhang J, Chen SY, Tang WJ, Turner JR, Yang F*, Liang H*, Qin HL*, Wu XY*. ACF7 regulates inflammatory colitis and intestinal wound response by orchestrating tight junction dynamics. Nature Communications, 2017, 8, 15375.
6. Zhu MH, Xu SH, Li GC, Xu G, Zhang ZL, Liang H*, Yang F*. Development of a high-efficacy and low-toxicity cobalt(II) agent for targeting inhibition of tumor growth through mitochondrial damage-mediated chemotherapy and immunotherapy. Journal of Medicinal Chemistry, 2025, 68, 13113–13126. (药物化学顶级期刊，IF=6.8)
7. Xu G, Liang QY, Gao LJ, Xu SH, Luo WC, Wu QM, Li JY, Zhang ZL, Liang H, Yang F*. Developing an arene bi-nuclear ruthenium(II) complex to induce ferroptosis and activate the cGAS-STING pathway: targeted inhibiting growth and metastasis of triple negative breast cancer. Journal of Medicinal Chemistry, 2024, 67, 19573–19585.
8. Li WJ, Li SH, Zhu MH, Xu G, Man XY, Zhang ZL, Liang H*, Yang F*. Developing a rhodium(III) complex to reprogram the tumor immune and metabolic microenvironments: overcoming multidrug resistance and metastasis in non-small cell lung cancer. Journal of Medicinal Chemistry, 2024, 67, 17243–17258.
9. Jiang M, Li WJ, Liang JZ, Pang M, Li SH, Xu G, Zhu MH, Liang H, Zhang ZL*, Yang F*. Developing a palladium(II) agent to overcome multi-drug resistance and metastasis of liver tumor by targeted multi-acting on tumor cell, inactivating cancer-associated fibroblast and activating immune response. Journal of Medicinal Chemistry, 2024, 67, 16296–16310.
10. Man XY, Li WJ, Zhu MH, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Rational design of a hetero-multinuclear gadolinium(III)-copper(II) complex: integrating magnetic resonance imaging, photoacoustic imaging, mild photothermal therapy, chemotherapy and immunotherapy of cancer. Journal of Medicinal Chemistry, 2024, 67, 15606–15619.
11. Man XY, Li SH, Xu G, Li WJ, Zhu MH, Zhang ZL, Liang H*, Yang F*. Developing a copper(II) isopropyl 2-pyridyl ketone thiosemicarbazone compound based on the IB subdomain of human serum albumin–indomethacin complex: inhibiting tumor growth by remodeling the tumor microenvironment. Journal of Medicinal Chemistry, 2024, 67, 5744–5757.
12. Li WJ, Li T, Pan Y, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Designing a mitochondria-targeted theranostic cyclometalated iridium(Ⅲ) complex: Overcoming cisplatin resistance and inhibiting tumor metastasis through necroptosis and immune response. Journal of Medicinal Chemistry, 2024, 67, 3843–3859. (高被引论文)
13. Zhu MH, Man XY, Yang TF, Li WJ, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Developing a hetero-trinuclear erbium(III)-copper(II) complex based on apoferritin: targeted photoacoustic imaging and multi-modality therapy of tumor. Journal of Medicinal Chemistry, 2023, 66, 15424−15436.
14. Li WJ, Li SH, Xu G, Man XY, Yang TF, Zhang ZL, Liang H*, Yang F*. Developing a ruthenium(III) complex to trigger gasdermin E-mediated pyroptosis and immune response based on decitabine and liposomes: targeting inhibition of gastric tumor growth and metastasis. Journal of Medicinal Chemistry, 2023, 66, 13072–13085.
15. Li WJ, Li SH, Zhang ZL, Xu G, Man XY, Yang F*, Liang H*. Developing a multi-targeted anticancer palladium(II) agent based on the His-242 residue in IIA subdomain of human serum albumin. Journal of Medicinal Chemistry, 2023, 66, 8564–8579.
16. Man XY, Yang TF, Li WJ, Li SH, Xu G, Zhang ZL, Liang H*, Yang F*. Developing a gadolinium(III) compound based on apoferritin for targeted magnetic resonance imaging and dual-modal therapy of cancer. Journal of Medicinal Chemistry, 2023, 66: 7268–7279.
17. Zhang ZL, Zhang JZ, Yang TF, Li SH, Xu G, Liang H*, Yang F*. Developing an anticancer platinum(II) compound based on the uniqueness of human serum albumin. Journal of Medicinal Chemistry, 2023, 66: 5669–5684.
18. Yang TF, Zhang ZL, Zhang JZ, Li YP, Li WJ, Liang H*, Yang F*. Developing a gallium(III) agent based on properties of the tumor micro-environment and lactoferrin: Achieving two-agent co-delivery and multi-targeted combination therapy of cancer. Journal of Medicinal Chemistry, 2023, 66: 793−803.
19. Jiang M, Zhang ZL, Li WJ, Man XY, Sun HB, Liang H*, Yang F*. Developing a copper(II) agent based on His-146 and His-242 residues of human serum albumin nanoparticles: integration to overcome cisplatin resistance and inhibit the metastasis of nonsmall cell lung cancer. Journal of Medicinal Chemistry, 2022, 65: 9447−9458.
20. Zhang ZL, Yang TF, Zhang JZ, Li WJ, Li SH, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on human serum albumin nanoparticles: integrating bioimaging and therapy. Journal of Medicinal Chemistry, 2022, 65: 5392−5406.
21. Gou Y, Jia XY, Hou LX, Deng JG, Huang GJ, Jiang HW*, Yang F*. Dithiocarbazate−Fe III , −Co III , −Ni II , and −Zn II complexes: design, synthesis, structure, and anticancer evaluation. Journal of Medicinal Chemistry, 2022, 65: 6677−6689.
22. Zhang JZ, JiangM, Li SH, Zhang ZL, Sun HB, Yang F*,Liang H*. Developing a novel anticancer gold(III) agent to integrate chemotherapy and immunotherapy. Journal of Medicinal Chemistry, 2021, 64: 6777−6791.
23. Jiang M, Chu Y, Yang TF, Li WJ, Zhang ZL, Sun HB, Liang H*, Yang F*. Developing a novel indium(III) agent based on liposomes to overcome cisplatin-induced resistance in breast cancer by multitargeting the tumor microenvironment components. Journal of Medicinal Chemistry, 2021, 64: 14587−14602.
24. Gou Y, Chen MR, Li SH, Deng JG, Li JL, Fang GH, Yang F*, Huang GJ*. Dithiocarbazate-copper complexes for bioimaging and treatment of pancreaticcancer. Journal of Medicinal Chemistry, 2021, 64: 5485−5499.
25. Zhang JZ, Zhang ZL, Jiang M, Li SH, Yuan HL, Sun HB, Yang F*, Liang H*. Developing a novel gold(III) agent to treat glioma based onthe unique properties of apoferritin nanoparticles: inducing lethal autophagyand apoptosis. Journal of Medicinal Chemistry, 2020, 63: 13695−13708.
26. Zhang ZL, Yu P, Gou Y, Zhang JZ, Li SH, Cai ML, Sun HB, Yang F*, Liang H*. Novel brain-tumor-inhibiting copper(II) compound based on a human serum albumin (HSA)-cell penetrating peptide conjugate. Journal of Medicinal Chemistry, 2019, 62: 10630−10644.
27. Qi JX, Gou Y, Zhang Y, Yang K, Chen SF, Liu L, Wu XY, Wang T*, Zhang W*, Yang F*. Developing anticancer ferric prodrugs based on the N-donor residues of human serum albumin carrier IIA subdomain. Journal of Medicinal Chemistry, 2016, 59: 7497−7511.
代表性科研项目:
(1) 国家自然科学基金(22577017): 基于脱铁铁蛋白发展脑胶质瘤诊疗一体化金属(Gd、Ir)化合物（2026.1-2029.12）
(2) 国家自然科学基金(32560228): 抗肿瘤先导金属化合物与拓扑异构酶II/人血清白蛋白复合物的结构和功能（2026.1-2029.12）
(3) 国家自然科学基金(22077021): 基于人血清白蛋白IB/IIA亚域N-供体氨基酸发展抗肿瘤多靶点先导缩氨基硫脲金属(Fe、Pt、Ru、Au和Os)化合物（2021.1-2024.12）
(4) 国家自然科学基金(31460232): 抗凋亡蛋白(Bcl-2)/人血清白蛋白与抗肿瘤无机药物复合物的结构和功能（2015.1-2018.12）
(5) 国家自然科学基金-重点项目(21431001): 基于中药活性成分金属抗肿瘤配合物研究（主持子课题, 2015.1-2019.12）
(6) 国家自然科学基金(21171043): 抗肿瘤先导植物药、金属基药物与人血清白蛋白相互作用研究（2012.1-2015.12）
(7) 国家自然科学基金(31060121): 外膜蛋白-CusC的功能和结构基础（2011.1-2013.12）
(8) 教育部创新团队(IRT1225)：天然活性物质的发现、结构改造与功能（主持子课题, 2013.1-2015.12）
(9) 广西自然科学基金-创新团队项目： 蛋白质导向的抗肿瘤金属药物研究（2022.4-2026.3）
(10) 广西自然科学基金-重大项目：抑制抗凋亡蛋白活性金属药物的HSA递送体系的研究（2017.9-2021.8）
(11) 广西自然科学基金-杰出青年项目：过渡金属离子外排泵的结构生物学研究（2013.4-2016.3）
(12) 广西自然科学基金-重点项目：人血清白蛋白的适体筛选及其相互作用研究（2014.4-2017.3）
(13) 广西自然科学基金-重点项目：人血清白蛋白结合抗肿瘤金属基药物的分子机制研究（2012.4-2015.3）
(14) 广西高等学校高水平创新团队: 蛋白质载药体系（2017.1-2019.12）
(15) 广西院士后备培养工程：无机药物及其载运体系研究 （主持子课题, 2017.7-2022.6）
(16) 广西重大人才项目：新型抗肿瘤药物的研究 （2025.10-2030.9）
学术兼职:
《中国现代应用药学》, 编委, 2021-至今
《Pharmaceutical Fronts》, 编委, 2024-至今
《Current Cancer Therapy Reviews》(Bentham Science出版社), 编委, 2022-至今
《Current Pharmaceutical Design》, 客座主编, 2015-2016
国家自然科学基金项目通讯评审专家
美国化学会、Elsevier和Wiley等SCI国际刊物审稿专家